Liisa Bayko: I just had — I wanted to drill down a little bit more on the gentler conditioning regimen program. So what are you working on in terms of approaching that? What do you think are the most I guess, promising approaches out there. What is your thinking on when something like that could come to market? And I guess if someone else developed something like that, is that something you think you could fold into your program? And how do you think about sort of owning something like that versus someone else and your access to it?
Baisong Mei: Thank you very much for the question. Well, first, I just want to say that I’m super excited to have joined Editas. I’m so impressed with the foundational technology as well as really the truly excellent of this team. Coming to your question, of course, my other conditioning is such a crucial parameter for many therapeutic indications, oncology, so many therapy indications as well as, of course, the sickle cell disease. And so it’s been sought after to have motor conditioning regimens for many years. And we are, of course, monitoring the landscape and keeping very active on all of the various approaches that are out there as well as I’ve only been here for 7 days, so I’m getting up to speed on what the team is doing internally. I can root this over to Gilmore for additional comments. But of course, we are going to be very active in terms of this aspect.
Gilmore O’Neill: Thanks very much, Liisa. And with regard to how we would fold it in, I think your — I think you’ve actually touched on it which is that mito-conditioning, as Linda said, is generalizable across multiple elements or I say, therapeutic areas when it comes to the use of stem cell transplantation. And so we see any advances certainly in systemic therapeutics. — that impact and can result in minor conditioning, having an impact across expanding the eligibility of the eligible patient population. And obviously, that would have an impact on our therapeutic use. Obviously, looking beyond mito-conditioning, the in vivo target hematopoietic stem cells is an additional step which could eliminate the need for any conditioning as well as actually further reduce the burden on patients and health care systems by eliminating the need for harvesting, freezing and collecting CD34 positive stem cells.
And the way we would see it rolling in is we would see the development of a milder conditioning therapeutic of whatever sponsor adopted at transplant centers in their transplant protocols and then generalizing across multiple therapeutic spaces that use stem cell transplantation.
Operator: Our next question comes from Brian Cheng with JPMorgan.
Brian Cheng: Just one quick one from me on manufacturing. On the facility, do you have any insights on when this facility could come online? How does that timing potentially fit into the pivotal portion of the ongoing studies. And as you will discuss with the FDA on CMC in the second half this year, are there any specific important items that you need to get aligned with the agency?
Gilmore O’Neill: Thanks very much, Brian. With regard to online, the timing of this deal and this expansion is really tied to our BLA readiness planning. And so we are happy with the progress with Azure and the readiness to be online at the time that’s appropriate to support our BLA. With regard to FDA alignment, I’m not going to go into the specifics here. But essentially, we just want to confirm and agree with our understanding around the guidance and their interpretation of the guidance and our program as it pertains to cell therapeutics [ph].
Operator: Our next question is from Steve Seedhouse with Raymond James.
Unidentified Analyst: This is Nick [ph] on for Steve. We were wondering if and how you’re measuring off-target edits or translocations for EDIT-301 and RUBY or EDITHAL and whether or not you plan to share those data.
Gilmore O’Neill: Thanks very much, Nick, for the question. Indeed, we actually have a comprehensive. We have a comprehensive set of assays for looking at off-target edits. We’re actually very happy with the data we have seen. Interestingly, we actually saw following our proposed set of assays that controls to the agency that many of those remarks were reflected in the guidance that was published after our submissions. But we’re actually very happy we’re seeing off-target edits. We believe that it really supports and validates our approach to choose an ASK1 a CRISPR enzyme which, as you know, is differentiated both for its efficiency as well as its specificity and very low indeed, undetectable off-target editing. So, all is actually moving consistently with the selection of that enzyme and its prioritization in our portfolio.
Operator: Ladies and gentlemen, we have reached the end of our question-and-answer session which concludes today’s call. Thank you once again for your participation. You may now disconnect.
